Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 5 Margin 2 Expansion 4 Platform 3 Financial 3

latest quarter score

Earnings Reports

17
Arrowhead Pharmaceuticals (ARWR) Q3 2026: Redemplo Prescriptions Double, SHTG Data Unlocks $3B+ Opportunity
August 05, 2026
11
Arrowhead Pharmaceuticals (ARWR) Q1 2026: $1.33B Capital Infusion Powers Pipeline, Redemplo Launch Sets Commercial Trajectory
June 15, 2026
14
Arrowhead Pharmaceuticals (ARWR) Q2 2026: Redemplo Scripts Surge 40% as Cardiometabolic Pipeline Nears Data Catalyst
May 08, 2026
10
Arrowhead (ARWR) Q4 2025: $829M Partner Revenue Sets Stage for First Commercial Launch and Pipeline Acceleration
November 26, 2025
9
Arrowhead (ARWR) Q3 2025: $230M New Milestones, Four Phase III Readouts Drive Commercial Inflection
August 08, 2025
12
Arrowhead Pharmaceuticals (ARWR) Q2 2025: $543M Sarepta Deal Fuels Transition to Commercial Stage
May 12, 2025
Arrowhead Pharmaceuticals (ARWR) Q4 2024: $825M Sarepta Deal Reshapes Pipeline and Extends Cash Runway to 2028
November 26, 2024
Arrowhead Pharmaceuticals (ARWR) Q3 2024: $500M Debt Facility Secured as Plazaciran Nears Commercialization
August 08, 2024
Arrowhead Pharmaceuticals (ARWR) Q2 2024: R&D Spend Rises 29% as Cardiometabolic Pipeline Accelerates Toward Commercialization
May 09, 2024
Arrowhead Pharmaceuticals (ARWR) Q1 2024: $100M Operating Burn Cut Reshapes Clinical Investment Priorities
February 06, 2024
Arrowhead Pharmaceuticals (ARWR) Q3 2023: Pipeline Expands Toward 20 Clinical Assets as Partner Milestones Add $70M
August 07, 2023
Arrowhead Pharmaceuticals (ARWR) Q2 2023: 90% Knockdown in Pulmonary RNAi Validates Platform Expansion
May 02, 2023

Browse all companies